



US008895546B2

(12) **United States Patent**
Cartt et al.

(10) **Patent No.:** **US 8,895,546 B2**
(45) **Date of Patent:** **Nov. 25, 2014**

(54) **ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS**
(75) Inventors: **Steve Cartt**, San Carlos, CA (US); **David Medeiros**, South San Francisco, CA (US); **Garry Thomas Gwozdz**, Jim Thorpe, PA (US); **Andrew Loxley**, Philadelphia, PA (US); **Mark Mitchnick**, East Hampton, NY (US); **David Hale**, San Diego, CA (US); **Edward T. Maggio**, San Diego, CA (US)

3,722,371 A 3/1973 Boyle
3,849,341 A 11/1974 Lambeiti
3,987,052 A 10/1976 Hester, Jr.
4,280,957 A 7/1981 Walsler et al.
4,397,951 A 8/1983 Taki et al.
4,608,278 A 8/1986 Frank et al.
4,748,158 A 5/1988 Biermann et al.
4,826,689 A 5/1989 Violanto et al.
4,868,289 A 9/1989 Magnusson et al.
4,921,838 A 5/1990 Catsimpoolas et al.
4,973,465 A 11/1990 Baurain et al.
4,997,454 A 3/1991 Violanto et al.
5,091,188 A 2/1992 Haynes
5,100,591 A 3/1992 Leclef et al.
5,118,528 A 6/1992 Fessi et al.
5,145,684 A 9/1992 Liversidge et al.
5,182,258 A 1/1993 Chiou
5,188,837 A 2/1993 Domb
5,192,528 A 3/1993 Radhakrishnan et al.
5,236,707 A 8/1993 Stewart
5,268,461 A 12/1993 Shoji et al.
5,308,531 A 5/1994 Urfer et al.
5,317,010 A 5/1994 Pang et al.
5,369,095 A 11/1994 Kee et al.
5,457,100 A 10/1995 Daniel
5,550,220 A 8/1996 Meyer et al.
5,560,932 A 10/1996 Bagchi et al.
5,639,733 A 6/1997 Koike et al.
5,661,130 A 8/1997 Meezan et al.
5,662,883 A 9/1997 Bagchi et al.
5,665,331 A 9/1997 Bagchi et al.
5,716,642 A 2/1998 Bagchi et al.
5,738,845 A 4/1998 Imakawa
5,780,062 A 7/1998 Frank et al.
5,789,375 A 8/1998 Mukae et al.

(73) Assignee: **Hale Biopharma Ventures, LLC**, Encinitas, CA (US)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/495,942**

(22) Filed: **Jun. 13, 2012**

(65) **Prior Publication Data**
US 2013/0065886 A1 Mar. 14, 2013

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/413,439, filed on Mar. 27, 2009.
(60) Provisional application No. 61/497,017, filed on Jun. 14, 2011, provisional application No. 61/570,110, filed on Dec. 13, 2011.

(51) **Int. Cl.**
A61K 31/55 (2006.01)
A61K 9/00 (2006.01)
A61K 31/355 (2006.01)
A61K 31/5513 (2006.01)
A61K 45/06 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/355** (2013.01); **A61K 9/0043** (2013.01); **A61K 31/5513** (2013.01); **A61K 9/008** (2013.01); **A61K 45/06** (2013.01)
USPC **514/221**

(58) **Field of Classification Search**
USPC 514/221
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

3,102,116 A 8/1963 Chase et al.
3,109,843 A 11/1963 Reeder et al.
3,136,815 A 6/1964 Reeder et al.
3,243,427 A 3/1966 Reeder et al.
3,296,249 A 1/1967 Bell
3,299,053 A 1/1967 Archer et al.
3,340,253 A 9/1967 Reeder et al.
3,371,085 A 2/1968 Reeder et al.
3,374,225 A 3/1968 Reeder et al.
3,547,828 A 12/1970 Mansfield et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0396777 A1 11/1990
EP 606046 7/1994

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 60/148,464, filed Aug. 12, 1999, Noe.
Wermeling et al., "Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers," *Anesthesia & Analgesia* 103 (2):344-349 (2006).
EP08747813 Supplementary Search Report dated Jun. 2, 2010.
PCT/US09/38696 Search Report dated Sep. 28, 2009.
PCT/US08/62961 Search Report dated Jul. 25, 2008.
PCT/US2012/042311 Search Report dated Aug. 31, 2012.
AU application 2009228093 First exam report dated Jul. 19, 2013.

(Continued)

Primary Examiner — Adam C Milligan
(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.



(56)

References Cited

U.S. PATENT DOCUMENTS

5,795,896	A	8/1998	Löfroth et al.
5,814,607	A	9/1998	Patton
5,817,634	A	10/1998	Meezan et al.
5,831,089	A	11/1998	Huber
5,861,510	A	1/1999	Piscipio et al.
5,863,949	A	1/1999	Robinson et al.
5,955,425	A	9/1999	Morley et al.
5,981,719	A	11/1999	Woiszwillow et al.
6,004,574	A	12/1999	Backstrom et al.
6,090,925	A	7/2000	Woiszwillow et al.
6,143,211	A	11/2000	Mathiowitz et al.
6,165,484	A	12/2000	Raad et al.
6,193,985	B1	2/2001	Sonne
6,235,224	B1	5/2001	Mathiowitz et al.
6,254,854	B1	7/2001	Edwards et al.
6,268,053	B1	7/2001	Woiszwillow et al.
6,316,029	B1	11/2001	Jain et al.
6,316,410	B1	11/2001	Barbier et al.
6,375,986	B1	4/2002	Ryde et al.
6,395,300	B1	5/2002	Straub et al.
6,428,814	B1	8/2002	Bosch et al.
6,458,387	B1	10/2002	Scott et al.
6,461,591	B1	10/2002	Keller et al.
6,482,834	B2	11/2002	Spada et al.
6,495,498	B2	12/2002	Niemiec et al.
6,524,557	B1	2/2003	Backstrom et al.
6,607,784	B2	8/2003	Kipp et al.
6,610,271	B2	8/2003	Wermeling
6,616,914	B2	9/2003	Ward et al.
6,627,211	B1	9/2003	Choi et al.
6,794,357	B1	9/2004	Backstrom et al.
6,869,617	B2	3/2005	Kipp
6,884,436	B2	4/2005	Kipp
6,908,626	B2	6/2005	Cooper et al.
6,932,962	B1	8/2005	Backstrom et al.
6,991,785	B2	1/2006	Frey
7,008,920	B2	3/2006	Kimura et al.
7,037,528	B2	5/2006	Kipp
7,132,112	B2	11/2006	Choi et al.
7,434,579	B2	10/2008	Young et al.
8,530,463	B2	9/2013	Cartt
2001/0042932	A1	11/2001	Mathiowitz et al.
2002/0110524	A1	8/2002	Cowan et al.
2002/0127278	A1	9/2002	Kipp
2002/0141971	A1	10/2002	Frey
2002/0168402	A1	11/2002	Kipp
2003/0017203	A1	1/2003	Crotts et al.
2003/0031719	A1	2/2003	Kipp
2003/0040497	A1	2/2003	Teng et al.
2003/0087820	A1	5/2003	Young et al.
2003/0100755	A1	5/2003	Sham et al.
2003/0118547	A1	6/2003	Vandenberg
2003/0118594	A1	6/2003	Nag et al.
2003/0158206	A1	8/2003	Billotte et al.
2003/0170206	A1	9/2003	Rasmussen et al.
2003/0181411	A1	9/2003	Bosch et al.
2004/0115135	A1	6/2004	Quay
2004/0126358	A1	7/2004	Warne et al.
2004/0141923	A1	7/2004	Dugger et al.
2004/0147473	A1	7/2004	Warriell, Jr.
2004/0258663	A1	12/2004	Quay et al.
2005/0130260	A1	6/2005	Linden et al.
2005/0234101	A1	10/2005	Stenkamp et al.
2006/0045869	A1	3/2006	Meezan et al.
2006/0046962	A1	3/2006	Meezan et al.
2006/0046969	A1	3/2006	Maggio
2006/0106227	A1	5/2006	Reddy et al.
2006/0147386	A1	7/2006	Wermeling
2006/0198896	A1	9/2006	Liversidge et al.
2007/0059254	A1	3/2007	Singh
2007/0098805	A1	5/2007	Liversidge
2007/0298010	A1	12/2007	Maggio
2008/0200418	A1	8/2008	Maggio
2008/0279784	A1	11/2008	Cartt
2008/0299079	A1	12/2008	Meezan et al.
2009/0047347	A1	2/2009	Maggio
2009/0130216	A1	5/2009	Cartt
2009/0163447	A1	6/2009	Maggio
2009/0258865	A1	10/2009	Cartt et al.
2009/0297619	A1	12/2009	Swanson et al.
2009/0304801	A1	12/2009	Liversidge et al.
2010/0068209	A1	3/2010	Maggio
2010/0203119	A1	8/2010	Leane et al.
2010/0209485	A1	8/2010	Maggio
2011/0172211	A1	7/2011	Back et al.
2011/0257096	A1	10/2011	Maggio
2012/0196941	A1	8/2012	Maggio
2013/0065886	A1	3/2013	Cartt

FOREIGN PATENT DOCUMENTS

EP	00780386	6/1997
EP	0818442	1/1998
EP	931 788	7/1999
EP	0945485	9/1999
EP	1004578	5/2000
EP	1417972 A1	5/2004
JP	1-151528	6/1989
JP	2003-505403	2/2003
JP	2005-508939	4/2005
JP	2007-510722	4/2007
WO	WO-9005719	5/1990
WO	WO-91-19481	12/1991
WO	WO-94-05262 A1	3/1994
WO	WO-95-00151 A1	1/1995
WO	WO-95-31217 A1	11/1995
WO	WO-9627583	9/1996
WO	WO-9633172	10/1996
WO	WO-97-14407 A1	4/1997
WO	WO-9803516	1/1998
WO	WO-9807697	2/1998
WO	WO-9830566	7/1998
WO	WO-9833768	8/1998
WO	WO-9834915	8/1998
WO	WO-9834918	8/1998
WO	WO-9907675	2/1999
WO	WO-9929667	6/1999
WO	WO-9952889	10/1999
WO	WO-9952910	10/1999
WO	WO-00-01390 A1	1/2000
WO	WO-0074681	12/2000
WO	WO-03-055464	7/2003
WO	WO-2005-018565 A2	3/2005
WO	WO-2005-044234 A2	5/2005
WO	WO-2005-089768	9/2005
WO	WO-2005-117830 A1	12/2005
WO	WO-2006-025882 A2	3/2006
WO	WO-2006-055603	5/2006
WO	WO-2006-075123 A1	7/2006
WO	WO-2006-088894	8/2006
WO	WO-2007-043057 A2	4/2007
WO	WO-2007-144081 A1	12/2007
WO	WO-2008-027395 A2	3/2008
WO	WO-2009-120933 A2	10/2009

OTHER PUBLICATIONS

EP application 09723906.5 Extended European search report dated Jun. 3, 2013.

JP application 2010-507633 Decision of refusal dated Jul. 9, 2013.

Ahsan et al., "Effects of the permeability enhancers, tetradecylmaltoside and dimethyl- β -cyclodextrin, on insulin movement across human bronchial epithelial cells", *European Journal of Pharmaceutical Sciences*, 2003; 20: 27-34.

Ahsan et al., "Sucrose cocoate, a component of cosmetic preparations enhances nasal and ocular peptide absorption", *Int J Pharm*, 2003; 251: 195-203.

Albert et al., "Pharmacokinetics of diphenhydramine in man", *J. Pharmacokinetic, Biopharm.*, 3(3): 159-170 (1975).

Arnold et al., "Correlation of tetradecylmaltoside induced increases

(56)

References Cited

OTHER PUBLICATIONS

- Beam et al., "Blood, Brain, Cerebrospinal Fluid Concentrations of Several Antibiotics in Rabbits with Intact and Inflamed Meninges", *Antimicrobial Agents and Chemotherapy*, Dec. 1977, pp. 710-716.
- Bhairi S.M., "A guide to the properties and uses of detergents in biological systems", *Calbiochem*, pp. 1-42 (2001).
- Birkett et al., "Bioavailability and First Pass Clearance", *Australian Prescriber*, 1991, pp. 14-16, vol. 14.
- Birkett et al., "How Drugs are Cleared by the Liver", *Australian Prescriber*, 1990, pp. 88-89, vol. 13, No. 4.
- CA 2,723,470 Office action dated Jun. 7, 2012.
- Castro et al., "Ecologically safe alkyl glucoside-based gemini surfactants", *ARKIVOC*, xii:253-267 (2005).
- Chavanpatil and Vavia, "Nasal drug delivery of sumatriptan succinate", *Pharmazie*, May 2005:60(5):347-349.
- Chen et al., "Peptide Drug Permeation Enhancement by Select Classes of Lipids", presented at the 45th American Society of Cell Biology, S.F., CA, Dec. 10-14, 2005; 1 page total.
- Chen-Quay et al., "Identification of tight junction modulating lipids", *J. Pharm. Sci.*, 98(2):606-619 (2009).
- Chiou et al., "Improvement of Systemic Absorption of Insulin Through Eyes with Absorption Enhancers", *Journal of Pharmaceutical Sciences*, Oct. 1989, pp. 815-818, vol. 78, No. 10.
- Chiou et al., "Systemic Delivery of Insulin Through Eyes to Lower the Glucose Concentration", *Journal of Ocular Pharmacology*, 1989, pp. 81-91, vol. 5, No. 1.
- Chinese Patent Office from Application No. CN200980157305.0 dated Jan. 28, 2013.
- Davis and Illum, "Absorption enhancers for nasal drug delivery", *Clin. Pharmacokine.*, 2003:42(13):107-28.
- De Vry and Schreiber, "Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action", *Neurosci. Biobehav. Rev.*, 24(3):341-53 (2000).
- Definition downloaded Sep. 13, 2012 at the medical-dictionary.thefreedictionary.com/p/encephalin.
- Definition of pilus, Merriam-Webster Medical Dictionary, <http://www.merriam-webster.com/medical/pilus>, accessed online on May 28, 2013.
- Definition of villus, Merriam-Webster Medical Dictionary, <http://www.merriam-webster.com/medical/villus>, accessed online on May 28, 2013.
- Drewe et al., "Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether", *Br. J. Pharmacol.*, 108(2):298-303 (1993).
- Duquesnoy et al., "Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration", *Eur. J. Pharm. Sci.*, 6(2):99-104 (1998).
- Edwards CM., "GLP-1: target for a new class of antidiabetic agents?", *J.R. Soc. Med.*, 97(6):270-274 (2004).
- Eley and Triumalashetty, "In vitro assessment of alkylglycosides as permeability enhancers", *AAPS PharmSciTech.*, 2(3): article 19, pp. 1-7 (2001).
- European Search Report (ESR) from EP 09 83 5809 dated Nov. 13, 2012.
- Fricker et al., "Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations", *Br. J. Pharmacol.*, 117(1):217-23 (1996).
- Gordon et al., "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts", *Proceedings of the National Academy of Sciences of the United States of America*, Nov. 1985, pp. 7419-7423, vol. 82.
- Hathcox and Beuchat, "Inhibitory effects of sucrose fatty acid esters, alone and in combination with ethylenediaminetetraacetic acid and other organic acids, on viability of *Escherichia coli* 0157:H7", *Food Microbiology*, vol. 13, Issue 3, 213-225 (1996).
- Hovgaard et al., "Insulin Stabilization and GI Absorption", *Journal of Controlled Release*, Mar. 1992, pp. 99-108, vol. 19, Issue 1-3.
- Hovgaard et al., "Stabilization of insulin by alkylmaltosides. A. Spec-
- Hovgaard et al., "Stabilization of Insulin by Alkylmaltosides. B. Oral Absorption in Vivo in Rats", *International Journal of Pharmaceutics*, 1996, pp. 115-121, vol. 132.
- International Search Report (ISR) from PCT/US2011/056735 dated Jun. 22, 2012.
- JP2010-507633 Office Action dated Oct. 23, 2012.
- Katzung, B., "Basic and Clinical Pharmacology, 7th Edition", Appleton & Lange: Stamford, Connecticut, 1998, pp. 34-49.
- Lacy, C, et al., "Drug Information Handbook, 7th Edition 1999-2000" Lexi-Comp, Inc., 1999, pp. 163-164.
- Lahat et al., "Intranasal midazolam for childhood seizures", *The Lancet*, 1998; 352: 620.
- Lehninger et al., "Principles of Biochemistry with an Extended Discussion of Oxygen-Binding Proteins", 1982, pp. 150-151, Worth Publishers, Inc.
- Maa and Prestrelski, "Biopharmaceutical powders: particle formation and formulation considerations", *Curr. Pharm. Biotechnol.*, 1(3):283-302 (2000).
- Material Safety Data Sheet for Anatrace, Inc. product n-Dodecyl-β-d-Maltopyranoside, Anagrade, Dated: Jan. 25, 1994 and Revised: Jul. 15, 2004, http://media.affymetrix.com/estore/browse/level_3/category_and_products.jsp?category=35843&categoryClicked=35843&expand=true&parent=35900, access online on Dec. 13, 2012.
- Mathew N.T., "Serotonin 1D (5-HT1D) agonists and other agents in acute migraine", *Neurol. Clin.*, 15(1):61-83 (1997).
- Matsumura et al., "Surface activities, biodegradability and antimicrobial properties of n-alkyl glucosides, mannosides and galactosides", *Journal of the America Oil Chemists' Society*, 67(12):996-1001 (1990).
- Moses et al., "Insulin Administered Intranasally as an Insulin-Bite Salt Aerosol—Effectiveness and Reproducibility in Normal and Diabetic Subjects", *Diabetes*, Nov. 1983, pp. 1040-1047, vol. 32.
- Murakami et al., "Assessment of Enhancing Ability of Medium-Chain Alkyl Saccharides as New Absorption Enhancers in Rat Rectum", *International Journal of Pharmaceutics*, Feb. 1992, pp. 159-169, vol. 79, Issue 1-3].
- Ogiso et al., "Percutaneous Absorption of Elcatonin Chemical and Hypocalcemic Effect in Rat", *Chemical & Pharmaceutical Bulletin*, Feb. 1991, pp. 449-453, vol. 39, Issue 2, The Pharmaceutical Society of Japan, Tokyo, Japan.
- Olesen et al., "The Headaches", *Lippincott Williams & Wilkins*, p. 474 (2005).
- Paulsson and Edsman, "Controlled drug release from Gels using surfactant aggregates. II Vesicles formed from mixtures of amphiphilic drugs and oppositely charged surfactants", *Pharm. Res.*, 18(11):1586-1592 (2001).
- PCT/US08/62961 International Preliminary Report on Patentability dated Nov. 10, 2009.
- PCT/US09/38696 International Preliminary Report on Patentability dated Sep. 28, 2010.
- Phillips, A., "The challenge of gene therapy and DNA delivery", *J. Pharm Pharmacology* 53: 1169-1174, 2001.
- Pillion et al., "Synthetic long-chain alkyl maltoside and alkyl sucrose esters as enhancers of nasal insulin absorption", *J. Pharm. Sci.*, 91:1456-1462 (2002).
- Pillion et al., "Systemic Absorption of Insulin Delivered Topically to the Rat Eye", *Investigative Ophthalmology & Visual Science*, Nov. 1991, pp. 3021-3027, vol. 32, Issue 12.
- Pirollo et al., "Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies", *Cancer Res.* 68(5): 1247-1250, 2008.
- Richards R.M., "Inactivation of resistant *Pseudomonas aeruginosa* by antibacterial combinations", *J. Pharm. Pharmacol.*, 23:136S-140S (1971).
- Salzman et al., "Intranasal Aerosolized Insulin", *The New England Journal of Medicine*, Apr. 25, 1985, pp. 1078-1084, vol. 312, Issue 17.
- Sanders et al., "Pharmacokinetics of ergotamine in healthy volun-

(56)

References Cited

OTHER PUBLICATIONS

Shim and Kim, "Administration Route Dependent Bioavailability of Interferon- α and Effect of Bile Salts on the Nasal Absorption", Drug Development and Industrial Pharmacy, 19(10):1183-1199 (1993).

Stevens and Guillet, "Use of Glucagon to Treat Neonatal Low-Output Congestive Heart Failure after Maternal Labetalol Therapy", The Journal of Pediatrics, Jul. 1995, pp. 151-153, vol. 127, Issue 1.

Swarbrick et al., Encyclopedia of Pharmaceutical Technology, Informa Health Care, 2nd edition, vol. 1, p. 918 (2002).

Tsuchido et al., "Lysis of *Bacillus subtilis* Cells by Glycerol and Sucrose Esters of Fatty Acids", Applied and Environmental Microbiology, vol. 53, No. 3, 505-508, 1987.

Türker et al., "Nasal route and drug delivery systems", Pharm. World Sci., 26(3):137-42 (2004).

Turton et al., "A role for glucagon-like peptide-1 in the central regulation of feeding", Nature, 1996; 379:69-72.

U.S. Appl. No. 12/116,842 Office action mailed May 25, 2011.

U.S. Appl. No. 12/116,842 Office action mailed Apr. 2, 2013.

U.S. Appl. No. 12/116,842 Office action mailed Nov. 15, 2011.

U.S. Appl. No. 12/116,842 Office action mailed Dec. 17, 2013.

U.S. Appl. No. 12/266,529 Office action mailed Jul. 10, 2012.

U.S. Appl. No. 12/266,529 Office action mailed Nov. 16, 2011.

U.S. Appl. No. 12/413,439 Office action mailed Mar. 18, 2011.

U.S. Appl. No. 12/413,439 Office action mailed Nov. 21, 2011.

Vidal et al., "Making sense of antisense", European Journal of Cancer, 41:2812-2818, 2005.

Watanabe et al., "Antibacterial Carbohydrate Monoesters Suppressing Cell Growth of *Streptococcus mutans* in the Presence of Sucrose", Current Microbiology, Sep. 2000, pp. 210-213, vol. 41, No. 3.

Weber and Benning, "Metabolism of orally administered alkyl betaglycosides in the mouse", J. Nutr., 114:247-254 (1984).

Webpage for Anatrace products of Affymetrix, http://www.affymetrix.com/estore/browse/level_three_category_and_products.jsp?category=35843&categoryldClicked=35843&expand=true&parent=35900, accessed online on Dec. 13, 2012.

Yamamoto et al., "The Ocular Route for Systemic Insulin Delivery in the Albino Rabbit", The Journal of Pharmacology and Experimental Therapeutics, Apr. 1989, pp. 249-255, vol. 249; No. 1.

Yu Xinrui et al., "Triptan Medicament and Migraine", World Pharmacy (Synthetic Drug and Biochemical Drug Formulation Fascicule), 22(2):91-92 (2001).

Fix, "Oral controlled release technology for peptides: status and future prospects", Pharmaceutical Research Dec. 1996; 13(12):1760-1764.

Hussain et al., "Absorption enhancers in pulmonary protein delivery," J Control Release, Jan. 8, 2004; 94(1):15-24.


Kissel et al., "Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects." Pharm Res. Jan. 1992; 9(1):52-57.

Kite et al., "Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro." J Clin Microbiol. Jul. 2004; 42(7):3073-3076.

Liu et al., "Interaction between chitosan and alkyl P-D-glucopyranoside and its effect on their antimicrobial activity", Carbohydrate Polymers. 2004; 56: 243-250.

U.S. Appl. No. 12/413,439 Office action mailed Jun. 19, 2014.

Figure 1



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.